Pharmacist | Jotup

Of Consumers, 70% Are Excited about GenAI in the Workplace, but Only 43% Are Enthusiastic about Its Impact on Daily Life

Retrieved on:

Mercoledì, Aprile 24, 2024

"These survey findings should be a wake-up call for business leaders, underscoring the need for responsible AI to inform everything they do.

Key Points:

"These survey findings should be a wake-up call for business leaders, underscoring the need for responsible AI to inform everything they do.
If consumers and employees have concerns around data privacy and the ethical use of GenAI, they will not embrace the technology."
Over 80% of survey participants demonstrated an awareness of GenAI, with a quarter already having used the technology.
Seventy-five percent reported that they have used a GenAI powered app or service in a variety of ways to address unmet needs.

University of Toronto scientists appointed as GSK chairs will advance drug delivery research and vaccine education tools for healthcare professionals

Retrieved on:

Martedì, Aprile 23, 2024

MISSISSAUGA, ON, April 23, 2024 /CNW/ - The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs.

Key Points:

MISSISSAUGA, ON, April 23, 2024 /CNW/ - The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs.
Bowen Li, assistant professor at the Leslie Dan Faculty of Pharmacy, University of Toronto, and the Canada Research Chair in RNA Vaccines & Therapeutics is the new GSK Chair in Pharmaceutics and Drug Delivery.
They enable continuous advancement in research and teaching and signify a long-term commitment to a specific area of impact.
The GSK Chair in Vaccine Education and Practice-Oriented Tools was established by GSK and the Leslie Dan Faculty of Pharmacy in 2023 through a joint investment of $ 3 million.

FDB Targeted Medication Warnings™ Earns Epic Toolbox Designation

Retrieved on:

Martedì, Aprile 23, 2024

Health Level 7, Hospital, FHIR, EHR, Software, Epic Systems, API, Toolbox, SMART, Medication, Patient safety, FDB, Patient, CDS, Health, First Databank, Pharmacist, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 23, 2024 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today that its FDB Targeted Medication Warnings™ solution has earned the new Toolbox designation from Epic Systems Corporation in the Medication Dosing Decision Support Toolbox category.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 23, 2024 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today that its FDB Targeted Medication Warnings™ solution has earned the new Toolbox designation from Epic Systems Corporation in the Medication Dosing Decision Support Toolbox category.
FDB Targeted Medication Warnings is part of the FDB PatientFirst™ suite of clinical decision support (CDS) solutions.
Several factors supported Targeted Medication Warnings' Toolbox designation, including its recently announced integration with CDS Hooks *.
Epic customers who want to learn more about how they can enhance efficiency for clinicians while improving patient safety and quality of patient care through advanced patient-specific medication decision support can find FDB Targeted Medication Warnings at vendorservices.epic.com/Showroom/Listing?id=851.

The Dutch Group Improves Efficiency and Information Visibility with Square 9

Retrieved on:

Martedì, Aprile 23, 2024

AI, ERP, Clinic, Information management, Square, Pharmacist, Medical device

NEW HAVEN, Conn., April 23, 2024 /PRNewswire-PRWeb/ -- The Dutch Group, a fuel, convenience store, and medical chain with over 50 consecutive years of positive sales growth, has streamlined its accounts payables processes using an AI-assisted solution from Square 9. This intelligent information management solution takes advantage of AI document capture to manage invoices and eliminate data entry into the Dutch Group's ERP system from PDI Technologies.

Key Points:

This intelligent information management solution takes advantage of AI document capture to manage invoices and eliminate data entry into the Dutch Group's ERP system from PDI Technologies.
With Square 9, all the information is in there.
By centralizing information access and facilitating remote payables processing across their Clinic and Pharmacy locations in 2 U.S. states, the Dutch Group has drastically improved efficiency and ensured their staff have all the information they need without sacrificing their controls and best practices.
Accounts payable automation solutions involving high volumes of vendors face significant hurdles without AI-assisted capture like Square 9's TransformAI .

Federal Court Rules CVS Acted With "Deliberate Indifference" When It Adopted Rx Program That Discriminates Against People Living With HIV, Says Consumer Watchdog

Retrieved on:

Venerdì, Aprile 19, 2024

CVS, Pharmacy, LLP, Supreme court, CVS Pharmacy, Senior counsel, District court, Pressure, Consumer Watchdog, Medicine, CVS Caremark, Order, Failure, Multimedia, HIV, Affordable Care Act, Lawyer, Pharmacist, Health insurance

The lawsuit alleges that the program cuts off access to knowledgeable pharmacists and other critical benefits and services essential for people living with HIV.

Key Points:

The lawsuit alleges that the program cuts off access to knowledgeable pharmacists and other critical benefits and services essential for people living with HIV.
The four HIV-positive "John Doe" Plaintiffs in the case are represented by lawyers for the non-profit Consumer Watchdog and Whatley Kallas, LLP.
"… Plaintiffs sufficiently allege that Defendants implemented The Program by "utiliz[ing] its discretion" under its contracts with employers and 'offer[ing] financial inducements to plan sponsors.
Furthermore...CVS Caremark has an ongoing ability to alter plan terms and the prescription drug benefits provided thereunder to Class Members.

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit

Retrieved on:

Giovedì, Aprile 18, 2024

Weill Cornell Medicine, Hospital, Risk, Doctor of Philosophy, EACTS, Quality, Pharmacist, FACS, ICU, Patient safety, JD, CABG, Patient, DSM-IV codes, Associate

Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus.

Key Points:

Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus.
RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing elective cardiac surgery.
RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery.
Details of the oral presentation at EACTS 2nd Innovation Summit:
Presenter: Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine

Pharmacy Brands Canada Celebrates 200th Pharmacy Milestone with Expansion into Ontario

Retrieved on:

Martedì, Aprile 16, 2024

Marketing, Pharmacist, Pharmacy, Partnership, AB, Growth

EDMONTON, AB, April 16, 2024 /CNW/ - Pharmacy Brands Canada, the fastest-growing pharmacy banner program in Canada, is thrilled to announce its expansion into Ontario with the addition of its 200th location, Baywest Pharmacy, in Ajax, Ontario.

Key Points:

EDMONTON, AB, April 16, 2024 /CNW/ - Pharmacy Brands Canada, the fastest-growing pharmacy banner program in Canada, is thrilled to announce its expansion into Ontario with the addition of its 200th location, Baywest Pharmacy, in Ajax, Ontario.
This expansion represents a significant milestone for Pharmacy Brands Canada, which has experienced significant growth in Western Canada over the past three years and is proud to expand across Eastern Canada.
Since starting Pharmacy Brands Canada in 2020, our goal has been to be Western Canada's most sought-after pharmacy banner program.
Pharmacy Brands Canada is proud to extend its industry-leading economic support to independent pharmacies in Ontario and Eastern Canada.

BENECARD PBF WINS GOLD AWARD IN 2024 STEVIE® AWARDS FOR SALES & CUSTOMER SERVICE

Retrieved on:

Lunedì, Aprile 15, 2024

Bellagio (resort), Pharmacist, City centre, Contact, Stevie Awards, Customer service, Organization, International business, Nursing

The organization was a Gold Winner for Contact Center of the Year, up to 100 seats in the other services industry category.

Key Points:

The organization was a Gold Winner for Contact Center of the Year, up to 100 seats in the other services industry category.
The awards are presented by the Stevie Awards, which organizes several of the world's leading business awards shows including the prestigious American Business Awards® and International Business Awards®.
Entries were stringently evaluated and considered in more than 90 categories for customer service and contact center achievements.
"The BeneCard PBF award submission, 'Our Members Are Our Purpose,' reflected the critical role that our Customer Service, Contact Center team representatives play as they interact directly with our members.

Lafayette Square Provides Debt Financing for Med Learning Group

Retrieved on:

Giovedì, Aprile 11, 2024

ACCME, Accreditation Council, CME, MLG, Environment, Nursing, Accreditation, Physician, MED, Health, Continuing medical education, Pharmacist, Growth

MIAMI and NEW YORK, April 11, 2024 /PRNewswire/ -- Lafayette Square , a national investment platform, announced today that it has provided incremental debt financing to support the growth of Med Learning Group , LLC ("MLG").

Key Points:

MIAMI and NEW YORK, April 11, 2024 /PRNewswire/ -- Lafayette Square , a national investment platform, announced today that it has provided incremental debt financing to support the growth of Med Learning Group , LLC ("MLG").
"We're pleased to provide capital to Med Learning Group and DW Healthcare Partners as they work to expand this important business," said Blair Badham, Managing Director at Lafayette Square.
"The Lafayette Square team has been a great fit for us as we continue to implement our growth plans for Med Learning Group," said Cam McDavid, Vice President at DW Healthcare Partners, the lead sponsor on the deal.
By delivering these solutions, Lafayette Square aims to reduce operational risk for its portfolio companies, help them attract and retain talent, and improve job quality.

XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube

Retrieved on:

Giovedì, Aprile 11, 2024

FDA, ASM, Disorder, Mouth, Food, Water, Pharmacist, Seizure, CNS, Tablet, Patient, Epilepsy, Central nervous system, MBA, Pharmaceutical industry

"The approval addresses the needs of patients living with epilepsy who are currently taking, or who may benefit from starting XCOPRI, but are unable to swallow the tablets whole," said Louis Ferrari, BS, RPh, MBA, vice president, Medical Affairs at SK Life Science.

Key Points:

"The approval addresses the needs of patients living with epilepsy who are currently taking, or who may benefit from starting XCOPRI, but are unable to swallow the tablets whole," said Louis Ferrari, BS, RPh, MBA, vice president, Medical Affairs at SK Life Science.
"In some patients, crushing tablets offers an additional option for dosing and administration by nasogastric tube.
This label update addresses an unmet need for this patient population and offers administration alternatives to the healthcare providers managing their care."
The FDA-approved label update considered the results of an open-label, randomized, single-center, 3-period, 6-sequence, balanced crossover study demonstrating bioequivalence between three administration routes including swallowing an intact tablet, as a crushed tablet suspended in water and taken orally, and as a crushed tablet suspended in water and administered via a nasogastric tube.